TABLE 1.
Clinical SPECT Acquisition Protocols for 177Lu Dosimetry
| Study | Treatment | Acquisition time (min) | Projections (n) | Frame time (s) | BPs (n) | Measurement time after injection (h) |
| Marin et al. (17) | 177Lu-DOTATATE | 21.3–42.7 | 64 | 40–80 | 1 | 4, 24, 144–192 |
| Sandström et al. (13) | 177Lu-DOTATATE | 30 | 60 | 60 | 1 | 1, 24, 96, 168 |
| Sandström et al. (14) | 177Lu-DOTATATE | 30 | 120 | 30 | 1 | 1, 24, 96, 168 |
| Hagmarker et al. (5) | 177Lu-DOTATATE | 30 | 120 | 30 | 1 | 24 |
| Santoro et al. (15) | 177Lu-DOTATATE | 22.5 | 60 | 45 | 1 | 4, 24, 72, 192 |
| Garkavij et al. (16) | 177Lu-DOTATATE | 22.5 | 60 | 45 | 1 | 24/96 |
| Delker at al. (18) | 177Lu-PSMA-617 | 21.3 | 128 | 20 | 1 | 24, 48, 72 |
| Kabasakal et al. (24) | 177Lu-PSMA | 20/BP | 96 | 25 | 2 | 24 |
| Hou et al. (19) | 177Lu-DOTATATE | 12–16 | 96 | 15–20 | 1 | 4, 24, 72 |
| Chicheportiche et al. (20) | 177Lu-DOTATATE | 15 | 60 | 30 | 1 | 20, 25, 168 |
| Beauregard et al. (23) | 177Lu-DOTATATE | 8–12 | 96 | 10–15 | 1 | 4, 24, 96 |
| Violet et al. (21) | 177Lu-PSMA-617 | (8–12)/BP | 96 | 10–15 | 2–3 | 4, 24, 96 |
| Hippeläinen et al. (22) | 177Lu-DOTATATE | 10.7 | 64 | 20 | 1 | 24, 48, 168 |
BP = bed position; PSMA = prostate-specific membrane antigen.